Concepedia

Jaymala Patel

JP

Statistics

Publications

5

Citations

528

H-Index

5

Active since

2017

Affiliations

Janssen (United States)(Current)

Johnson & Johnson (United States)

Springhouse

Jaymala Patel is an author at Janssen (United States) specializing in oncology, medicine, and castration-resistant prostate cancer therapy.

ORCID

Publications per year

2017–2024

5

Publications

5

Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice

Filippo Veglia, Ayumi Hashimoto, Harsh Dweep et al. · The Journal of Experimental Medicine · 2021 · 330 citations · Full text

, , +15

Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration‐resistant prostate cancer (CRPC)

Sumanta K. Pal, Jaymala Patel, Miaoling He et al. · Cancer · 2017 · 88 citations · Full text

, , +17

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

Diana Cortés‐Selva, Tatiana Perova, Sheri Skerget et al. · Blood · 2024 · 53 citations · Full text

, , +17

Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide

Jelena Belic, Ricarda Graf, Thomas Bauernhofer et al. · International Journal of Cancer · 2018 · 45 citations · Full text

, , +17

Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors

Ravit Geva, María Vieito, Jorge Ramón et al. · Cancer Immunology Immunotherapy · 2024 · 12 citations · Full text

, , +17

1–5 of 5